H
Hannelore I. Bax
Researcher at Erasmus University Medical Center
Publications - 7
Citations - 102
Hannelore I. Bax is an academic researcher from Erasmus University Medical Center. The author has contributed to research in topics: Ethambutol & Mycobacterium tuberculosis. The author has an hindex of 4, co-authored 7 publications receiving 32 citations.
Papers
More filters
Journal ArticleDOI
An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria.
TL;DR: In this article, the authors reviewed the in vitro activities of these new antibiotics, especially against ESBL and CPE microorganisms, potential side effects, and clinical studies in complicated urinary tract infection (cUTI), intra-abdominal infections (cIAI), and hospital-acquired pneumonia/ventilator-associatedpneumonia (HAP/VAP).
Journal ArticleDOI
New-Generation Antibiotics for Treatment of Gram-Positive Infections: A Review with Focus on Endocarditis and Osteomyelitis.
TL;DR: In the past 20 years, nine antibiotic drugs with predominant activity against Gram-positive bacteria have been introduced and approved by the Food and Drug Administration or the European Medicines Agency.
Journal ArticleDOI
The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs
Hannelore I. Bax,Irma A. J. M. Bakker-Woudenberg,Corné P. de Vogel,Aart van der Meijden,Annelies Verbon,Jurriaan E. M. de Steenwinkel +5 more
TL;DR: The in vitro time kill-kinetics assay provides important information on the mycobacterial killing dynamics of anti-tuberculosis drugs during the early phase of drug exposure, and is a valuable component of the preclinical modeling framework.
Journal ArticleDOI
Improving treatment outcome assessment in a mouse tuberculosis model.
Bas C. Mourik,Robin J. Svensson,Gerjo J. de Knegt,Hannelore I. Bax,Annelies Verbon,Ulrika S. H. Simonsson,Jurriaan E. M. de Steenwinkel +6 more
TL;DR: A new design for treatment outcome evaluation in a mouse TB model is provided, which provides accurate tools for assessment of the relationship between treatment length and predicted cure, allows for efficient comparison between regimens and adheres to the reduction and refinement principles of laboratory animal use.
Journal ArticleDOI
Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.
Bas C. Mourik,Gerjo J. de Knegt,Annelies Verbon,Johan W. Mouton,Hannelore I. Bax,Jurriaan E. M. de Steenwinkel +5 more
TL;DR: The data advocate the use of multiple mycobacterial strains, including a Beijing strain, to increase the translational value of mouse TB models evaluating treatment outcome, and support the notion that bactericidal activity in the first 2 months of treatment, as measured in clinical phase IIa/b trials, has limited predictive value for tuberculosis treatment outcome.